Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 98 entries
Sorted by: Best Match Show Resources per page
Prevention of stress ulcer bleeding: a review.

Scandinavian journal of gastroenterology. Supplement

Geus WP, Lamers CB.
PMID: 2277967
Scand J Gastroenterol Suppl. 1990;178:32-41. doi: 10.3109/00365529009093148.

The pathophysiology of stress ulcers is complex. There is either too much acid and pepsin or inadequate mucosal defenses. The incidence of upper GI bleeding due to stress ulcers in the ICU is 5-25% depending upon the minimum criterion...

Cite
Geus WP, Lamers CB. Prevention of stress ulcer bleeding: a review. Scand J Gastroenterol Suppl. 1990;178:32-41doi: 10.3109/00365529009093148.
Geus, W. P., & Lamers, C. B. (1990). Prevention of stress ulcer bleeding: a review. Scandinavian journal of gastroenterology. Supplement, 17832-41. https://doi.org/10.3109/00365529009093148
Geus, W P, and Lamers, C B. "Prevention of stress ulcer bleeding: a review." Scandinavian journal of gastroenterology. Supplement vol. 178 (1990): 32-41. doi: https://doi.org/10.3109/00365529009093148
Geus WP, Lamers CB. Prevention of stress ulcer bleeding: a review. Scand J Gastroenterol Suppl. 1990;178:32-41. doi: 10.3109/00365529009093148. PMID: 2277967.
Copy Download .nbib Format: NLM
Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction.

Journal of cachexia, sarcopenia and muscle

Faber J, Uitdehaag MJ, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M, Lamers C, Rümke H, Tilanus H, Siersema P, van Helvoort A, van der Gaast A.
PMID: 26136410
J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):32-44. doi: 10.1002/jcsm.12009. Epub 2015 Mar 31.

BACKGROUND: The majority of cancer patients loses weight and becomes malnourished during the course of their disease. Metabolic alterations and reduced immune competence lead to wasting and an increased risk of infectious complications. In the present study, the effect...

Cite
Faber J, Uitdehaag MJ, Spaander M, et al. Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J Cachexia Sarcopenia Muscle. 2015;6(1):32-44doi: 10.1002/jcsm.12009.
Faber, J., Uitdehaag, M. J., Spaander, M., van Steenbergen-Langeveld, S., Vos, P., Berkhout, M., Lamers, C., Rümke, H., Tilanus, H., Siersema, P., van Helvoort, A., & van der Gaast, A. (2015). Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. Journal of cachexia, sarcopenia and muscle, 6(1), 32-44. https://doi.org/10.1002/jcsm.12009
Faber, Joyce, et al. "Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction." Journal of cachexia, sarcopenia and muscle vol. 6,1 (2015): 32-44. doi: https://doi.org/10.1002/jcsm.12009
Faber J, Uitdehaag MJ, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M, Lamers C, Rümke H, Tilanus H, Siersema P, van Helvoort A, van der Gaast A. Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):32-44. doi: 10.1002/jcsm.12009. Epub 2015 Mar 31. PMID: 26136410; PMCID: PMC4435095.
Copy Download .nbib Format: NLM
Phototrophic pigment production with microalgae: biological constraints and opportunities.

Journal of phycology

Mulders KJ, Lamers PP, Martens DE, Wijffels RH.
PMID: 26988181
J Phycol. 2014 Apr;50(2):229-42. doi: 10.1111/jpy.12173. Epub 2014 Mar 15.

There is increasing interest in naturally produced colorants, and microalgae represent a bio-technologically interesting source due to their wide range of colored pigments, including chlorophylls (green), carotenoids (red, orange and yellow), and phycobiliproteins (red and blue). However, the concentration...

Cite
Mulders KJ, Lamers PP, Martens DE, et al. Phototrophic pigment production with microalgae: biological constraints and opportunities. J Phycol. 2014;50(2):229-42doi: 10.1111/jpy.12173.
Mulders, K. J., Lamers, P. P., Martens, D. E., & Wijffels, R. H. (2014). Phototrophic pigment production with microalgae: biological constraints and opportunities. Journal of phycology, 50(2), 229-42. https://doi.org/10.1111/jpy.12173
Mulders, Kim J M, et al. "Phototrophic pigment production with microalgae: biological constraints and opportunities." Journal of phycology vol. 50,2 (2014): 229-42. doi: https://doi.org/10.1111/jpy.12173
Mulders KJ, Lamers PP, Martens DE, Wijffels RH. Phototrophic pigment production with microalgae: biological constraints and opportunities. J Phycol. 2014 Apr;50(2):229-42. doi: 10.1111/jpy.12173. Epub 2014 Mar 15. PMID: 26988181.
Copy Download .nbib Format: NLM
Microalgal triacylglycerides production in outdoor batch-operated tubular PBRs.

Biotechnology for biofuels

Benvenuti G, Bosma R, Klok AJ, Ji F, Lamers PP, Barbosa MJ, Wijffels RH.
PMID: 26175799
Biotechnol Biofuels. 2015 Jul 15;8:100. doi: 10.1186/s13068-015-0283-2. eCollection 2015.

BACKGROUND: Microalgal triacylglycerides (TAGs) are a promising sustainable feedstock for the biofuel, chemical and food industry. However, industrial production of microalgal products for commodity markets is not yet economically viable, largely because of low microalgal productivity. The latter is...

Cite
Benvenuti G, Bosma R, Klok AJ, et al. Microalgal triacylglycerides production in outdoor batch-operated tubular PBRs. Biotechnol Biofuels. 2015;8:100doi: 10.1186/s13068-015-0283-2.
Benvenuti, G., Bosma, R., Klok, A. J., Ji, F., Lamers, P. P., Barbosa, M. J., & Wijffels, R. H. (2015). Microalgal triacylglycerides production in outdoor batch-operated tubular PBRs. Biotechnology for biofuels, 8100. https://doi.org/10.1186/s13068-015-0283-2
Benvenuti, Giulia, et al. "Microalgal triacylglycerides production in outdoor batch-operated tubular PBRs." Biotechnology for biofuels vol. 8 (2015): 100. doi: https://doi.org/10.1186/s13068-015-0283-2
Benvenuti G, Bosma R, Klok AJ, Ji F, Lamers PP, Barbosa MJ, Wijffels RH. Microalgal triacylglycerides production in outdoor batch-operated tubular PBRs. Biotechnol Biofuels. 2015 Jul 15;8:100. doi: 10.1186/s13068-015-0283-2. eCollection 2015. PMID: 26175799; PMCID: PMC4501280.
Copy Download .nbib Format: NLM
cryo-EM structures of the .

eLife

Fernandez-Leiro R, Conrad J, Scheres SH, Lamers MH.
PMID: 26499492
Elife. 2015 Oct 24;4. doi: 10.7554/eLife.11134.

The replicative DNA polymerase PolIIIα from

Cite
Fernandez-Leiro R, Conrad J, Scheres SH, et al. cryo-EM structures of the . Elife. 2015;4doi: 10.7554/eLife.11134.
Fernandez-Leiro, R., Conrad, J., Scheres, S. H., & Lamers, M. H. (2015). cryo-EM structures of the . eLife, 4. https://doi.org/10.7554/eLife.11134
Fernandez-Leiro, Rafael, et al. "cryo-EM structures of the ." eLife vol. 4 (2015). doi: https://doi.org/10.7554/eLife.11134
Fernandez-Leiro R, Conrad J, Scheres SH, Lamers MH. cryo-EM structures of the . Elife. 2015 Oct 24;4. doi: 10.7554/eLife.11134. PMID: 26499492; PMCID: PMC4703070.
Copy Download .nbib Format: NLM
Health-based risk adjustment Improving the pharmacy-based cost group model to reduce gaming possibilities.

The European journal of health economics : HEPAC : health economics in prevention and care

Lamers LM, Vliet RC.
PMID: 15609177
Eur J Health Econ. 2003;4(2):107-14. doi: 10.1007/s10198-002-0159-9.

The pharmacy-based cost group (PCG) model uses medication prescribed to individuals in a base-year as marker for chronic conditions which are employed to adjust capitation payments to their health plans in the subsequent year. Although the PCG model enhances...

Cite
Lamers LM, Vliet RC. Health-based risk adjustment Improving the pharmacy-based cost group model to reduce gaming possibilities. Eur J Health Econ. 2003;4(2):107-14doi: 10.1007/s10198-002-0159-9.
Lamers, L. M., & Vliet, R. C. (2003). Health-based risk adjustment Improving the pharmacy-based cost group model to reduce gaming possibilities. The European journal of health economics : HEPAC : health economics in prevention and care, 4(2), 107-14. https://doi.org/10.1007/s10198-002-0159-9
Lamers, L M, and Vliet, R C J A. "Health-based risk adjustment Improving the pharmacy-based cost group model to reduce gaming possibilities." The European journal of health economics : HEPAC : health economics in prevention and care vol. 4,2 (2003): 107-14. doi: https://doi.org/10.1007/s10198-002-0159-9
Lamers LM, Vliet RC. Health-based risk adjustment Improving the pharmacy-based cost group model to reduce gaming possibilities. Eur J Health Econ. 2003;4(2):107-14. doi: 10.1007/s10198-002-0159-9. PMID: 15609177.
Copy Download .nbib Format: NLM
Risk-adjusted capitation payment systems for health insurance plans in a competitive market.

Expert review of pharmacoeconomics & outcomes research

Lamers LM, van Vliet RC, van de Ven WP.
PMID: 19807388
Expert Rev Pharmacoecon Outcomes Res. 2003 Oct;3(5):541-9. doi: 10.1586/14737167.3.5.541.

Adequate risk-adjustment is critical to the success of market-oriented healthcare reforms in many countries. Regulated competition among insurers and providers is often a crucial element in these reforms. Consumers may then choose among competing health insurance plans, which are...

Cite
Lamers LM, van Vliet RC, van de Ven WP. Risk-adjusted capitation payment systems for health insurance plans in a competitive market. Expert Rev Pharmacoecon Outcomes Res. 2003;3(5):541-9doi: 10.1586/14737167.3.5.541.
Lamers, L. M., van Vliet, R. C., & van de Ven, W. P. (2003). Risk-adjusted capitation payment systems for health insurance plans in a competitive market. Expert review of pharmacoeconomics & outcomes research, 3(5), 541-9. https://doi.org/10.1586/14737167.3.5.541
Lamers, Leida M, et al. "Risk-adjusted capitation payment systems for health insurance plans in a competitive market." Expert review of pharmacoeconomics & outcomes research vol. 3,5 (2003): 541-9. doi: https://doi.org/10.1586/14737167.3.5.541
Lamers LM, van Vliet RC, van de Ven WP. Risk-adjusted capitation payment systems for health insurance plans in a competitive market. Expert Rev Pharmacoecon Outcomes Res. 2003 Oct;3(5):541-9. doi: 10.1586/14737167.3.5.541. PMID: 19807388.
Copy Download .nbib Format: NLM
Metabolic modeling of Chlamydomonas reinhardtii: energy requirements for photoautotrophic growth and maintenance.

Journal of applied phycology

Kliphuis AM, Klok AJ, Martens DE, Lamers PP, Janssen M, Wijffels RH.
PMID: 22427720
J Appl Phycol. 2012 Apr;24(2):253-266. doi: 10.1007/s10811-011-9674-3. Epub 2011 Apr 15.

In this study, a metabolic network describing the primary metabolism of Chlamydomonas reinhardtii was constructed. By performing chemostat experiments at different growth rates, energy parameters for maintenance and biomass formation were determined. The chemostats were run at low irradiances...

Cite
Kliphuis AM, Klok AJ, Martens DE, et al. Metabolic modeling of Chlamydomonas reinhardtii: energy requirements for photoautotrophic growth and maintenance. J Appl Phycol. 2011;24(2):253-266doi: 10.1007/s10811-011-9674-3.
Kliphuis, A. M., Klok, A. J., Martens, D. E., Lamers, P. P., Janssen, M., & Wijffels, R. H. (2012). Metabolic modeling of Chlamydomonas reinhardtii: energy requirements for photoautotrophic growth and maintenance. Journal of applied phycology, 24(2), 253-266. https://doi.org/10.1007/s10811-011-9674-3
Kliphuis, Anna M J, et al. "Metabolic modeling of Chlamydomonas reinhardtii: energy requirements for photoautotrophic growth and maintenance." Journal of applied phycology vol. 24,2 (2012): 253-266. doi: https://doi.org/10.1007/s10811-011-9674-3
Kliphuis AM, Klok AJ, Martens DE, Lamers PP, Janssen M, Wijffels RH. Metabolic modeling of Chlamydomonas reinhardtii: energy requirements for photoautotrophic growth and maintenance. J Appl Phycol. 2012 Apr;24(2):253-266. doi: 10.1007/s10811-011-9674-3. Epub 2011 Apr 15. PMID: 22427720; PMCID: PMC3289792.
Copy Download .nbib Format: NLM
Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center.

Hepatology communications

Rojas SA, Godino JG, Northrup A, Khasira M, Tam A, Asmus L, Frenette C, Ramers CB.
PMID: 33681676
Hepatol Commun. 2020 Dec 21;5(3):412-423. doi: 10.1002/hep4.1617. eCollection 2021 Mar.

Hepatitis C virus (HCV) is a major cause of cirrhosis, liver cancer, and mortality in the United States. We assessed the effectiveness of decentralized HCV treatment delivered by nurse practitioners (NPs), primary care physicians (PMDs), or an infectious disease...

Cite
Rojas SA, Godino JG, Northrup A, et al. Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center. Hepatol Commun. 2020;5(3):412-423doi: 10.1002/hep4.1617.
Rojas, S. A., Godino, J. G., Northrup, A., Khasira, M., Tam, A., Asmus, L., Frenette, C., & Ramers, C. B. (2021). Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center. Hepatology communications, 5(3), 412-423. https://doi.org/10.1002/hep4.1617
Rojas, Sarah A, et al. "Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center." Hepatology communications vol. 5,3 (2021): 412-423. doi: https://doi.org/10.1002/hep4.1617
Rojas SA, Godino JG, Northrup A, Khasira M, Tam A, Asmus L, Frenette C, Ramers CB. Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center. Hepatol Commun. 2020 Dec 21;5(3):412-423. doi: 10.1002/hep4.1617. eCollection 2021 Mar. PMID: 33681676; PMCID: PMC7917265.
Copy Download .nbib Format: NLM
Formative applications of ongoing visual inspection for trial-based functional analysis: A proof of concept.

Journal of applied behavior analysis

Standish CM, Bailey KM, Lambert JM, Copeland BA, Banerjee I, Lamers ME.
PMID: 34263947
J Appl Behav Anal. 2021 Sep;54(4):1526-1540. doi: 10.1002/jaba.866. Epub 2021 Jul 15.

Trial-based functional analysis (TBFA) possesses many strategic advantages which make it an ideal candidate for adoption in applied settings. Notwithstanding, some aspects of the analysis remain underdeveloped, including structured guidelines for interacting with obtained data reliably in formative and...

Cite
Standish CM, Bailey KM, Lambert JM, et al. Formative applications of ongoing visual inspection for trial-based functional analysis: A proof of concept. J Appl Behav Anal. 2021;54(4):1526-1540doi: 10.1002/jaba.866.
Standish, C. M., Bailey, K. M., Lambert, J. M., Copeland, B. A., Banerjee, I., & Lamers, M. E. (2021). Formative applications of ongoing visual inspection for trial-based functional analysis: A proof of concept. Journal of applied behavior analysis, 54(4), 1526-1540. https://doi.org/10.1002/jaba.866
Standish, Cassandra M, et al. "Formative applications of ongoing visual inspection for trial-based functional analysis: A proof of concept." Journal of applied behavior analysis vol. 54,4 (2021): 1526-1540. doi: https://doi.org/10.1002/jaba.866
Standish CM, Bailey KM, Lambert JM, Copeland BA, Banerjee I, Lamers ME. Formative applications of ongoing visual inspection for trial-based functional analysis: A proof of concept. J Appl Behav Anal. 2021 Sep;54(4):1526-1540. doi: 10.1002/jaba.866. Epub 2021 Jul 15. PMID: 34263947.
Copy Download .nbib Format: NLM
Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?.

Hepatology communications

Naggie S, Ramers CB.
PMID: 30976736
Hepatol Commun. 2019 Apr 01;3(4):453-455. doi: 10.1002/hep4.1347. eCollection 2019 Apr.

No abstract available.

Cite
Naggie S, Ramers CB. Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?. Hepatol Commun. 2019;3(4):453-455doi: 10.1002/hep4.1347.
Naggie, S., & Ramers, C. B. (2019). Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?. Hepatology communications, 3(4), 453-455. https://doi.org/10.1002/hep4.1347
Naggie, Susanna, and Ramers, Christian B. "Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?." Hepatology communications vol. 3,4 (2019): 453-455. doi: https://doi.org/10.1002/hep4.1347
Naggie S, Ramers CB. Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?. Hepatol Commun. 2019 Apr 01;3(4):453-455. doi: 10.1002/hep4.1347. eCollection 2019 Apr. PMID: 30976736; PMCID: PMC6442701.
Copy Download .nbib Format: NLM
Novel Antibiotics Targeting Bacterial Replicative DNA Polymerases.

Antibiotics (Basel, Switzerland)

Santos JA, Lamers MH.
PMID: 33158178
Antibiotics (Basel). 2020 Nov 04;9(11). doi: 10.3390/antibiotics9110776.

Multidrug resistance is a worldwide problem that is an increasing threat to global health. Therefore, the development of new antibiotics that inhibit novel targets is of great urgency. Some of the most successful antibiotics inhibit RNA transcription, RNA translation,...

Cite
Santos JA, Lamers MH. Novel Antibiotics Targeting Bacterial Replicative DNA Polymerases. Antibiotics (Basel). 2020;9(11)doi: 10.3390/antibiotics9110776.
Santos, J. A., & Lamers, M. H. (2020). Novel Antibiotics Targeting Bacterial Replicative DNA Polymerases. Antibiotics (Basel, Switzerland), 9(11), . https://doi.org/10.3390/antibiotics9110776
Santos, Joana A, and Lamers, Meindert H. "Novel Antibiotics Targeting Bacterial Replicative DNA Polymerases." Antibiotics (Basel, Switzerland) vol. 9,11 (2020). doi: https://doi.org/10.3390/antibiotics9110776
Santos JA, Lamers MH. Novel Antibiotics Targeting Bacterial Replicative DNA Polymerases. Antibiotics (Basel). 2020 Nov 04;9(11). doi: 10.3390/antibiotics9110776. PMID: 33158178; PMCID: PMC7694242.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 98 entries